Impax names new CEO and president
Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that its Board of Directors has appointed Paul M. Bisaro as Impax’s President and Chief Executive Officer and a member of the Company’s Board, effective March 27, 2017. Mr. Bisaro will succeed J. Kevin Buchi, who has served as Interim President and Chief Executive Officer since December of 2016.
With 25 years of generic and branded pharmaceutical experience, Mr. Bisaro, 56, is an accomplished global business leader who brings a successful record of leading operational execution and corporate transformation, resulting in company growth. He previously served as Executive Chairman of Allergan, plc (formerly Actavis, plc), President and CEO of Actavis (formerly Watson Pharmaceuticals, Inc.) and Chairman of the Board.